Streetbeat News

Stock Prices

KMX

Oppenheimer analyst Brian Nagel reiterated an Outperform rating on CarMax Inc (NYSE:KMX) with a price target of $105. CarMax has struggled with a bloated cost infrastructure and elevated used car prices. However, the analyst is optimistic that CarMax will emerge as a robust operator in the used car sector. The EPS forecast for Q2 is $0.73, consistent with Street figures. For FY23, the analyst predicts an EPS of $2.80, down from $3.03. CarMax shares closed higher by 0.62% to $78.25 on Tuesday.

Portfolio Pulse from Nabaparna Bhattacharya

September 26, 2023 | 8:20 pm

LMT

A significant bearish stance has been taken on Lockheed Martin (NYSE:LMT) by a large investor, as observed in the unusual options activity. The sentiment among these big-money traders is split between 40% bullish and 60% bearish. The whales have been targeting a price range from $400.0 to $500.0 for Lockheed Martin over the last 3 months. The price of LMT is currently down -1.01% at $408.75. Wells Fargo has upgraded its action to Equal-Weight with a price target of $440.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 8:16 pm

PIXY

ShiftPixy, Inc. (NASDAQ:PIXY) has announced a 1-for-24 reverse stock split effective from September 30, 2023. The new reversed shares will begin trading on Nasdaq on October 2, 2023.

Portfolio Pulse from Happy Mohamed

September 26, 2023 | 8:11 pm

CRDF

Cardiff Oncology, Inc. (NASDAQ:CRDF) has announced positive clinical data from its ongoing trials of onvansertib monotherapy and combination therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC). The company also plans to initiate a first-line trial for mPDAC. The data from the trials show promising results, with the pancreatic cancer Phase 2 trial showing greater efficacy compared to historical controls. The company will hold a conference call to discuss the preliminary data.

Portfolio Pulse from Happy Mohamed

September 26, 2023 | 8:09 pm

ADVM

Adverum Biotechnologies has reported Aflibercept protein level data from its LUNA Phase 2 trial. The company states that Ixo-vec has been well tolerated with a favorable preliminary safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:07 pm

MLKN

MillerKnoll (NASDAQ:MLKN) reported Q1 earnings of $0.37 per share, beating the analyst consensus estimate of $0.21 by 76.19%. However, this is a 15.91% decrease from the same period last year. The company also reported quarterly sales of $917.70 million, beating the estimate of $899.60 million by 2.01%, but marking a 14.95% decrease from last year.

Portfolio Pulse from Happy Mohamed

September 26, 2023 | 8:06 pm

AMT

A significant amount of unusual options activity has been detected for American Tower (NYSE:AMT), with a majority of investors taking a bearish stance. The price range targeted by these investors is between $150.0 and $180.0. The current price of AMT is $163.49, down by 1.35%. Morgan Stanley has maintained their Equal-Weight rating on American Tower, with a price target of $212.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 8:01 pm

COP

A significant amount of unusual options activity has been observed for ConocoPhillips (NYSE:COP), with a bearish stance being taken by a whale investor. Of the 22 strange trades detected, 45% were bullish and 54% were bearish. The total amount for puts was $383,464 and for calls was $827,317. Whales have been targeting a price range from $30.0 to $130.0 for ConocoPhillips over the last 3 months. The current price of COP is down -0.82% at $120.08.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 8:01 pm

MLI

Mueller Industries, Inc. has announced a two-for-one stock split in the form of a 100% stock dividend. The distribution date is set for October 20.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 8:01 pm

PLTR

A significant investor has taken a bearish stance on Palantir Technologies (NYSE:PLTR), with 60% of recent trades being bearish. The targeted price range for Palantir over the last 3 months is between $10.0 and $25.0. The current price of PLTR is down 2.0% at $13.94. HSBC, Wedbush, and Morgan Stanley have downgraded their actions on Palantir with price targets of $16, $25, and $9 respectively.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 8:01 pm